Has EP Biocomposites declared dividend?

No Dividend History Available

What is the technical trend for EP Biocomposites?

As of June 4, 2025, EP Biocomposites exhibits a mildly bearish technical trend, influenced by bearish moving averages and Bollinger Bands, despite mixed signals from the MACD and KST indicators.

As of 4 June 2025, the technical trend for EP Biocomposites has changed from does not qualify to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the monthly MACD is mildly bearish, suggesting mixed signals. The Bollinger Bands and moving averages both show a mildly bearish trend on the weekly and daily time frames. The KST is bearish on the weekly, reinforcing the overall bearish sentiment. The Dow Theory indicates a mildly bearish trend on the weekly, with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the moving averages and Bollinger Bands.

Who are the peers of the EP Biocomposites?

EP Biocomposites' peers include Antony Waste, Eco Recyc, Concord Enviro, and others, with varying management and growth risks. Notably, EP Biocomposites has a 1-year return of -35.14%, better than Gem Enviro's -77.16% but worse than Antony Waste's 6.68%.

Peers: The peers of EP Biocomposites are Antony Waste han, Eco Recyc., Concord Enviro, JITF Infra Logis, Denta Water, VVIP Infratech, Race Eco, Organic Recyclin, Gem Enviro, and Filtra Consult.<BR><BR>Quality Snapshot: Excellent management risk is observed at Eco Recyc., VVIP Infratech, and Gem Enviro, while Good management risk is found at EP Biocomposites, Antony Waste han, and Filtra Consult. Average management risk is present at Denta Water and Concord Enviro, while Below Average management risk is noted at Race Eco and Organic Recyclin. JITF Infra Logis does not qualify for management risk assessment. For growth, Excellent growth is seen at Eco Recyc., VVIP Infratech, and Organic Recyclin, while Good growth is noted at EP Biocomposites. Below Average growth is found at Antony Waste han, Concord Enviro, Denta Water, and Race Eco. JITF Infra Logis does not qualify for growth assessment. In terms of capital structure, Excellent capital structure is observed at Eco Recyc., Concord Enviro, and Gem Enviro, while Good capital structure is noted at EP Biocomposites, Antony Waste han, and Filtra Consult. Below Average capital structure is present at Race Eco and Organic Recyclin.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Antony Waste han at 6.68%, while the peer with the lowest is Gem Enviro at -77.16%. EP Biocomposites has a 1-year return of -35.14%, which is higher than Gem Enviro's return but lower than Antony Waste han's. Additionally, several peers, including JITF Infra Logis, VVIP Infratech, Race Eco, and Gem Enviro, have negative six-month returns.

Who are in the management team of EP Biocomposites?

As of March 2022, the management team of EP Biocomposites includes Rajkumar Kamat (Managing Director), Leena Kamat, Shreyas Nadkarni (Directors), and independent directors Nitin A Kunkolienker and Dinesh Shenoy.

As of March 2022, the management team of EP Biocomposites includes the following individuals:<BR><BR>- Rajkumar Kamat, Managing Director<BR>- Leena Kamat, Director<BR>- Shreyas Nadkarni, Director<BR>- Nitin A Kunkolienker, Independent Director<BR>- Dinesh Shenoy, Independent Director<BR><BR>These individuals make up the board of directors for the company.

What does EP Biocomposites do?

EP Biocomposites Ltd manufactures fibre reinforced polymer products and bio toilet solutions, classified as a Micro Cap company with a market cap of INR 19 Cr. The company was incorporated in 2020 and took over M/s. OM Ventures in 2021, but has not reported recent sales or profit data.

Overview: <BR>EP Biocomposites Ltd is engaged in the manufacture of fibre reinforced polymer products and bio toilet solutions, operating within the Other Utilities industry and classified as a Micro Cap company.<BR><BR>History: <BR>EP Biocomposites Limited was incorporated as a Public Limited Company on January 17, 2020. The company underwent a significant change when it took over the running business of M/s. OM Ventures on August 31, 2021. There is no recent sales or profit data reported.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 19 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 20.00 <BR>Industry P/E: 32 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.06 <BR>Return on Equity: 10.77% <BR>Price to Book: 1.95 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the EP Biocomposites?

The top shareholder of EP Biocomposites is Leena Rajkumar Kamat, holding 64.93% of the shares, with no pledged holdings. The highest public shareholder is Sambhav Dawar at 1.04%, while individual investors collectively own 26.41%.

The top shareholders of EP Biocomposites include the promoters, with Leena Rajkumar Kamat holding the largest share at 64.93%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sambhav Dawar, who owns 1.04%. Additionally, individual investors collectively hold 26.41% of the shares.

How big is EP Biocomposites?

As of 24th July, EP Biocomposites Ltd has a market capitalization of 22.00 Cr, classifying it as a Micro Cap company, with no available financial data for Net Sales and Net Profit for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds of 9.56 Cr and Total Assets of 15.07 Cr.

As of 24th July, <BR><BR>Market Cap: EP Biocomposites Ltd has a market capitalization of 22.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 9.56 Cr and Total Assets valued at 15.07 Cr.

When is the next results date for EP Biocomposites?

The next results date for EP Biocomposites is November 3, 2025.

The next results date for EP Biocomposites is scheduled for November 3, 2025.

How has been the historical performance of EP Biocomposites?

EP Biocomposites has shown steady growth in net sales and profitability from Mar'21 to Mar'25, with net sales increasing from 2.95 Cr to 12.01 Cr and profit after tax rising from 0.36 Cr to 1.03 Cr, despite fluctuations in raw material costs and stagnant cash flow. Total assets and liabilities also grew significantly during this period.

Answer:<BR>The historical performance of EP Biocomposites shows a progressive increase in net sales and profitability over the years, with notable fluctuations in certain metrics.<BR><BR>Breakdown:<BR>EP Biocomposites has demonstrated a steady growth in net sales, rising from 2.95 Cr in Mar'21 to 12.01 Cr in Mar'25. The total operating income followed a similar trend, increasing from 2.95 Cr in Mar'21 to 12.01 Cr in Mar'25. However, the raw material costs also escalated, reaching 7.98 Cr in Mar'25 from 1.79 Cr in Mar'21. Operating profit, excluding other income, improved from 0.46 Cr in Mar'21 to 1.78 Cr in Mar'25, while the overall operating profit, including other income, increased from 0.46 Cr to 1.89 Cr in the same period. Profit before tax peaked at 1.42 Cr in Mar'25, although it slightly declined from 1.57 Cr in Mar'24. Profit after tax also saw growth, reaching 1.03 Cr in Mar'25 compared to 0.36 Cr in Mar'21. The company's total assets increased significantly from 0.55 Cr in Mar'20 to 16.61 Cr in Mar'25, alongside total liabilities which rose from 0.55 Cr to 16.61 Cr. Cash flow from operating activities remained stagnant at 0.00 Cr in Mar'25, while cash and cash equivalents at the end of the period were stable at 1.00 Cr. Overall, EP Biocomposites has shown resilience and growth in its financial performance over the years, despite some fluctuations in profit margins and cash flow.

Is EP Biocomposites overvalued or undervalued?

As of November 19, 2025, EP Biocomposites is considered overvalued with a PE ratio of 15.35, an EV to EBIT of 11.15, and a year-to-date return of -45.03%, significantly underperforming compared to its peers and the Sensex.

As of 19 November 2025, EP Biocomposites has moved from a fair valuation to an expensive rating. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 15.35, an EV to EBIT of 11.15, and a ROCE of 12.38%. <BR><BR>In comparison to its peers, EP Biocomposites' PE ratio is significantly lower than that of Altius Telecom, which has a PE of 51.84, indicating that EP Biocomposites is not positioned favorably within its industry. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -45.03% compared to the Sensex's 9.02%, further reinforcing the notion that the stock is overvalued.

Which are the latest news on EP Biocomposites?

Why is EP Biocomposites falling/rising?

As of 04-Dec, EP Biocomposites Ltd's stock price is Rs 94.00, reflecting a significant decline of 11.11% and underperforming its sector. The stock has decreased 45.03% year-to-date and shows erratic trading patterns with low liquidity and consistent underperformance over various periods.

As of 04-Dec, EP Biocomposites Ltd's stock price is falling, currently at Rs 94.00, which reflects a decrease of Rs 11.75 or 11.11%. This decline is evident in the stock's performance over various periods, showing a significant drop of 11.70% over the past week and 22.28% over the past month. Year-to-date, the stock has decreased by 45.03%, while it has fallen 36.93% over the past year. <BR><BR>Today's trading activity indicates that the stock opened with a loss of 5.44% and reached an intraday low of Rs 94, which is only 3.72% above its 52-week low of Rs 90.5. Additionally, the stock has underperformed its sector by 10.83% today. The trading patterns reveal erratic behavior, as the stock did not trade on four out of the last twenty days, and it is currently trading below all key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day).<BR><BR>Despite a slight increase in delivery volume on November 28, which rose by 11.11% against the 5-day average, the overall liquidity remains low, with only 2% of the 5-day average traded value. This combination of poor performance metrics and trading behavior contributes to the stock's downward trend.